Exelixis Inc. (EXEL) - Market Cap to Net Income Ratio

Symbol and logo of brand Exelixis Inc (EXEL)

Exelixis, Inc. (EXEL) maintains its production capacities and patents within the US, ensuring business reliability. The company's P/E fluctuations visualize the balance between value and earnings, where the 19.60 level captures the latest values. Robust protection for Cabometyx and consistent demand generate excess profits, while surplus liquidity enables efficient investment in new developments, sustaining high margins.

EXEL exelixis.com: Price to Earnings Ratio in the range 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Exelixis Corp (EXEL)

- market price and analyst price targets:
Market Price exelixis.com|EXEL - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Exelixis, Inc.|EXEL - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Exelixis|EXEL - Company Net Assets|Market Value to Book Value exelixis.com|EXEL - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Exelixis, Inc.|EXEL - Long-Term Debt to Capital|Short-Term Debt to Capital Exelixis Inc.|EXEL - Company Debts|Debt to Net Assets Ratio Exelixis, Inc.|EXEL - Company Long-Term Debts|Short-Term Indebtedness Exelixis|Immediate Liquidity exelixis.com
- business earnings and investment ratios data:
EXEL - Net Income|Future Net Profit Exelixis, Inc.|EXEL - P/E Multiple|Projected Price to Earnings Ratio Exelixis Inc|EXEL - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Exelixis, Inc.|EXEL - Operating profit before deduction of amortization|Earnings per share for the trailing year Exelixis|EXEL - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months exelixis.com|EXEL - Earnings growth in current year|Expected earnings per share trend next year Exelixis, Inc.
Comprehensive company analysis:exelixis.com - EXEL
Finished products of Exelixis Corp

Assessing the market resilience of Exelixis, Inc. (EXEL) requires an analysis of the ratio between business value and net income. The integration of ESG standards into oncology development minimizes regulatory risks, thereby increasing the asset's fundamental value. The GURU.Markets toolkit visualizes the return on investment coefficient via the company's annual P/E, reflecting the current discounting of future earnings. Identifying local minimums for this indicator allows for the determination of the optimal entry point to maximize returns.

Key competitors

Market Cap to Earnings genmab.com GMAB|P/E Multiple NUVL|Kymera Therapeutics, Inc. (KYMR) - Market Cap to Net Income Ratio|IDEAYA Bio - Price to Earnings Ratio|Enliven Corp (ELVN) - Market Cap to Earnings|ORIC: Price to Earnings Ratio|Company Value to Net Income RLAY (relaytx.com)|NRIX (Nurix Therapeutics, Inc.) - Price to Earnings Ratio|TYRA: Market Price to Net Income Ratio|VSTM (Verastem Inc) - P/E Multiple|P/E Multiple Monte Rosa Corp|Price to Earnings Ratio Cullinan Therapeutics (CGEM)|IMRX (immuneering.com) - Company Value to Net Income|P/E Multiple CCCC (C4 Therapeutics)|Market Cap to Net Income Ratio Black Diamond Therapeutics, Inc.|Repare Rx - P/E Multiple|Market Cap to Earnings PMV Pharmaceuticals, Inc|KPTI (karyopharm.com) - Price to Earnings Ratio|PPCB: Market Price to Net Income Ratio|BGMS (Bio Green Med Solution) - P/E Multiple|Market Cap to Earnings Aadi Bio AADI|P/E Multiple ALRN|blueprintmedicines.com - Price to Earnings Multiple|GlycoMimetics - Price to Earnings Ratio|Company Value to Net Income SWTX